Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

RATIONALE An efficacious medical therapy for idiopathic pulmonary fibrosis (IPF) remains elusive. OBJECTIVES To explore the efficacy and safety of etanercept in the treatment of IPF. METHODS This was a randomized, prospective, double-blind, placebo-controlled, multicenter exploratory trial in subjects with clinically progressive IPF. Primary endpoints included changes in the percentage of predicted FVC and lung diffusing capacity for carbon monoxide corrected for hemoglobin (Dl(CO(Hb))) and change in the alveolar to arterial oxygen pressure difference P(a-a)(O(2)) at rest from baseline over 48 weeks. MEASUREMENTS AND MAIN RESULTS Eighty-eight subjects received subcutaneous etanercept (25 mg) or placebo twice weekly as their sole treatment for IPF. No differences in baseline demographics and disease status were detected between treatment groups; the mean time from first diagnosis was 13.6 months and mean FVC was 63.9% of predicted. At 48 weeks, no significant differences in efficacy endpoints were observed between the groups. A nonsignificant reduction in disease progression was seen in several physiologic, functional, and quality-of-life endpoints among subjects receiving etanercept. There was no difference in adverse events between treatment groups. CONCLUSIONS In this exploratory study in patients with clinically progressive IPF, etanercept was well tolerated. Although there were no differences in the predefined endpoints, a decreased rate of disease progression was observed on several measures. Further evaluation of TNF antagonists in the treatment of IPF may be warranted. Clinical trial registered with www.clinicaltrials.gov (NCT 00063869).

[1]  H. Collard,et al.  Acute exacerbations of idiopathic pulmonary fibrosis. , 2007, American journal of respiratory and critical care medicine.

[2]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[3]  G. Raghu Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches , 2006, European Respiratory Journal.

[4]  B. Haraoui,et al.  Interstitial pneumonitis associated with infliximab therapy. , 2006, The Journal of rheumatology.

[5]  D. Scott,et al.  Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.

[6]  G. Hunninghake Antioxidant therapy for idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[7]  Johny Verschakelen,et al.  High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[8]  G. Raghu,et al.  Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures , 2005, European Respiratory Journal.

[9]  G. Raghu,et al.  A RANDOMIZED PLACEBO CONTROLLED TRIAL ASSESSING THE EFFICACY AND SAFETY OF ETANERCEPT IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) , 2005 .

[10]  David A Lynch,et al.  High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. , 2005, American journal of respiratory and critical care medicine.

[11]  Andres Esteban,et al.  Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. , 2005, Chest.

[12]  T. Colby,et al.  Nonspecific Interstitial Pneumonia Versus Usual Interstitial Pneumonia: Differences in the Density Histogram of High-Resolution CT , 2005, Journal of computer assisted tomography.

[13]  F. Martinez,et al.  The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis , 2005, Annals of Internal Medicine.

[14]  A. Wells,et al.  Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.

[15]  D. Lynch,et al.  High-Resolution Computed Tomography Features of Nonspecific Interstitial Pneumonia and Usual Interstitial Pneumonia , 2005, Journal of computer assisted tomography.

[16]  V. Poletti,et al.  Differential diagnosis between usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP) assessed by high-resolution computed tomography (HRCT). , 2005, La Radiologia medica.

[17]  M. Dougados,et al.  Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks , 2005, Annals of the rheumatic diseases.

[18]  S. van der Linden,et al.  Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis , 2004, Annals of the rheumatic diseases.

[19]  J. Sharp,et al.  Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. , 2004, Arthritis and rheumatism.

[20]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[21]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[22]  A. Teirstein The elusive goal of therapy for usual interstitial pneumonia. , 2004, The New England journal of medicine.

[23]  A. Gottlieb,et al.  A randomized trial of etanercept as monotherapy for psoriasis. , 2003, Archives of dermatology.

[24]  A. Gottlieb,et al.  Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.

[25]  M. Dougados,et al.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. , 2003, Arthritis and rheumatism.

[26]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[27]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[28]  J. Braun,et al.  Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. , 2003, Arthritis and rheumatism.

[29]  G. Hunninghake,et al.  Idiopathic pulmonary fibrosis. , 2001, The New England journal of medicine.

[30]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[31]  P. Mease,et al.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.

[32]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[33]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[34]  V. Petkov,et al.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. , 1999, The New England journal of medicine.

[35]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[36]  W. Banks,et al.  Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. , 1998, Experimental lung research.

[37]  F. Graham,et al.  Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. , 1998, The American journal of pathology.

[38]  R. Thrall,et al.  Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. , 1997, The American journal of pathology.

[39]  P. Rubin,et al.  Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. , 1996, Radiation research.

[40]  A. Desmoulière,et al.  Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. , 1995, American journal of respiratory and critical care medicine.

[41]  J. Whitsett,et al.  Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. , 1995, The Journal of clinical investigation.

[42]  C. Vesin,et al.  Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. , 1994, The European respiratory journal.

[43]  G. Grau,et al.  Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. , 1993, The American journal of pathology.

[44]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[45]  Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[46]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.